Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

This World Kidney Day (13 March 2025), Boehringer Ingelheim (BI) has announced a new initiative aimed at detecting, ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...